KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Thermo Fisher Scientific (TMO) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Thermo Fisher Scientific (TMO) over the last 17 years, with Q3 2025 value amounting to $103.0 billion.

  • Thermo Fisher Scientific's Liabilities and Shareholders Equity rose 264.64% to $103.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $400.6 billion, marking a year-over-year increase of 150.27%. This contributed to the annual value of $97.3 billion for FY2024, which is 142.31% down from last year.
  • As of Q3 2025, Thermo Fisher Scientific's Liabilities and Shareholders Equity stood at $103.0 billion, which was up 264.64% from $101.2 billion recorded in Q2 2025.
  • Thermo Fisher Scientific's Liabilities and Shareholders Equity's 5-year high stood at $103.0 billion during Q3 2025, with a 5-year trough of $65.9 billion in Q2 2021.
  • For the 5-year period, Thermo Fisher Scientific's Liabilities and Shareholders Equity averaged around $92.3 billion, with its median value being $97.1 billion (2023).
  • Per our database at Business Quant, Thermo Fisher Scientific's Liabilities and Shareholders Equity soared by 4067.28% in 2022 and then crashed by 142.31% in 2024.
  • Over the past 5 years, Thermo Fisher Scientific's Liabilities and Shareholders Equity (Quarter) stood at $95.1 billion in 2021, then grew by 2.14% to $97.2 billion in 2022, then rose by 1.62% to $98.7 billion in 2023, then dropped by 1.42% to $97.3 billion in 2024, then grew by 5.86% to $103.0 billion in 2025.
  • Its Liabilities and Shareholders Equity was $103.0 billion in Q3 2025, compared to $101.2 billion in Q2 2025 and $99.0 billion in Q1 2025.